Wall Street Zen Upgrades Teleflex (NYSE:TFX) to “Hold”

Teleflex (NYSE:TFX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.

Several other equities research analysts also recently issued reports on TFX. Raymond James Financial restated an “outperform” rating and issued a $150.00 price target on shares of Teleflex in a report on Friday, May 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Bank of America upgraded Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price objective for the company in a research report on Monday, April 13th. Zacks Research raised Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Finally, BMO Capital Markets started coverage on shares of Teleflex in a report on Wednesday, July 8th. They set an “outperform” rating and a $159.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $150.50.

Teleflex Trading Down 1.7%

Shares of NYSE TFX opened at $132.66 on Friday. Teleflex has a twelve month low of $100.18 and a twelve month high of $145.00. The stock has a market cap of $5.87 billion, a price-to-earnings ratio of -5.70, a P/E/G ratio of 0.90 and a beta of 0.81. The company has a quick ratio of 2.12, a current ratio of 2.60 and a debt-to-equity ratio of 0.94. The company’s fifty day moving average is $131.83 and its 200-day moving average is $122.91.

Teleflex (NYSE:TFX) last released its quarterly earnings data on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.48. The business had revenue of $570.33 million during the quarter, compared to analysts’ expectations of $559.59 million. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The firm’s quarterly revenue was up 28.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.73 EPS. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. Equities research analysts predict that Teleflex will post 7.44 EPS for the current year.

Institutional Trading of Teleflex

Hedge funds have recently added to or reduced their stakes in the company. Ruffer LLP bought a new stake in Teleflex during the fourth quarter worth $5,154,000. Waterfront Wealth Inc. bought a new position in shares of Teleflex in the 4th quarter valued at $2,050,000. Eos Management L.P. bought a new position in shares of Teleflex in the 4th quarter valued at $3,763,000. Universal Beteiligungs und Servicegesellschaft mbH increased its stake in shares of Teleflex by 227.5% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 27,822 shares of the medical technology company’s stock valued at $3,395,000 after purchasing an additional 19,327 shares during the last quarter. Finally, First Eagle Investment Management LLC raised its holdings in shares of Teleflex by 163.4% during the 4th quarter. First Eagle Investment Management LLC now owns 84,300 shares of the medical technology company’s stock worth $10,288,000 after buying an additional 52,300 shares in the last quarter. 95.62% of the stock is owned by institutional investors and hedge funds.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.